Record numbers of biotechs are going public. Here's how they're performing.
Bio Pharma Dive
OCTOBER 26, 2020
Initial public offerings have fueled biotech's boom. A new database built by BioPharma Dive will help you keep track of them as they happen.
Sat.Oct 24, 2020 - Fri.Oct 30, 2020
361 
Web analytics should tell a story
World of DTC Marketing
OCTOBER 30, 2020
IN SUMMARY: Web analytics really has nothing to do with numbers. They have everything to do with what the numbers are telling you about your audience and messaging. DTC marketers need to get out of the mindset of using raw numbers and ask their web analytics people for insights instead. One of the services we often provide for clients is a deep-dive web analytics report.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Singapore Halts Dosing of Two Flu Shots After 59 Deaths in South Korea
BioSpace
OCTOBER 27, 2020
South Korea, on the other hand, indicated they would continue their state-run vaccination program because they did not find a direct link between the deaths and the vaccinations.
Pharma 2030: Will payers fund more preventive care programmes?
pharmaphorum
OCTOBER 26, 2020
Preventive care programmes are key to better health outcomes, but several factors are limiting their uptake. A new analysis looks at these barriers and asks how they could be overcome. Over the past decade, many healthcare systems have worked to expand their focus on health maintenance and disease prevention as several studies have indicated that preventive care services can play a significant role in improving general health while helping reduce long term healthcare costs.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bristol Myers taps machine-learning biotech for help finding ALS drugs
Bio Pharma Dive
OCTOBER 28, 2020
The companies hope Insitro's technology can lead to a deeper understanding of how ALS progresses and, in turn, help them discover better treatments.
Health consumers: A long way off
World of DTC Marketing
OCTOBER 27, 2020
We keep hearing the term “consumers of health” but the American healthcare system is too profitable to allow people to be consumers of healthcare. “The need for action now is clear. Health care costs are climbing so fast they may soon threaten the quality of care and access to care which Americans enjoy.” Ronald Reagan. What if … people got a fair ROI for healthcare spending the way we expect a reasonable return from other investments?
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Ipsen’s UK MD on adapting business to COVID-19
pharmaphorum
OCTOBER 30, 2020
Since entering the pharmaceutical industry as a graduate trainee in the late 1990s, Asad Mohsin Ali’s career has taken him across the business from Novartis, MSD and Tesaro, before joining global biopharma Ipsen. He tells us how the company has responded to COVID and how he’d like to see the UK industry grow in the future. As managing director, Ipsen UK & Ireland, Ali heads up one of Ipsen’s three global hubs, as well as chairing a UK & Ireland Site Steering Committee overseeing 900 peop
Atea, riding interest in COVID-19 drugs, pulls off one of 2020's top biotech IPOs
Bio Pharma Dive
OCTOBER 30, 2020
The Boston startup's initial public offering is the fourth-largest in biotech this year, according to data compiled by BioPharma Dive.
Leaders must make their organizations and the world better
World of DTC Marketing
OCTOBER 28, 2020
SUMMARY: Leaders have a duty to make their companies stronger and help make the world a better place. Leadership is crucial in providing a unified vision. Pharma CEO’s shouldn’t believe that their products, alone, will help make the world a stronger place. People want and need more. I believe there is a significant leadership vacuum in healthcare.
Regeneron Halts Enrollment of Critically Ill Patients in COVID-19 Antibody Trial
BioSpace
OCTOBER 29, 2020
The decision to halt critically ill patients was made in response to Regeneron’s independent safety board finding a potential safety signal and an unfavorable risk-benefit profile of the monoclonal antibody therapy in a subgroup of patients requiring high-flow oxygen or mechanical ventilation.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Why 72% of patients don’t feel listened to by pharma
pharmaphorum
OCTOBER 28, 2020
Claus Møldrup explores research showing that patients want their voice to be heard more by pharma, and asks what a truly effective feedback loop for medicines might look like. The democratisation of data opens up improvements to virtually every product and service across virtually every sector — bar one. Pharma remains stubbornly closed to feedback, with potentially damaging consequences for the industry, healthcare systems and patients.
Mirati cancer drug results spark hopes of outperforming Amgen's
Bio Pharma Dive
OCTOBER 26, 2020
The biotech's KRAS-blocking pill trails Amgen's sotorasib in development, but early data suggest it might match the bar set by Amgen.
Unfair balance
World of DTC Marketing
OCTOBER 29, 2020
WHAT’S UP? : It’s time to admit that the FDA is completely out of touch regarding DTC advertising. Fair balance is not being read in ads or listened to on TV, and the language used in fair balance is too often complicated for online health seekers. I just finished an analysis of a pharma clients website using their analytics. Rather than just report the numbers my report “tells a story” that managers can use to justify changes to the product website.
Novo Nordisk Ends Development of NN9828, Shifts Focus to Pandemic Initiatives
BioSpace
OCTOBER 29, 2020
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
What can we learn from women’s health data?
pharmaphorum
OCTOBER 27, 2020
Analysing real-world health data could help overcome the bias towards men in traditional medical research, says Sensyne Health’s Dr Lucy Mackillop. Collecting and analysing anonymised patient data has the potential to generate valuable insights that can catalyse research, lead to improved patient care, and power the development of new treatments.
5 takeaways from the FDA's closely watched coronavirus vaccine meeting
Bio Pharma Dive
OCTOBER 24, 2020
Experts convened by the regulators debated how much data would warrant an approval, while pressing government officials on their distribution plans.
IQVIA: tap the right talent to lead digital transformation
Outsourcing Pharma
OCTOBER 30, 2020
In order to effectively handle collection and analysis of huge volumes of vital data, a leader from IQVIA advises bringing on people up to the challenge.
Novartis Expands Footprint in Gene and Cell Therapy with Vedere Bio Acquisition
BioSpace
OCTOBER 28, 2020
Novartis acquired Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with Vedere Bio’s gene therapy platforms for ophthalmic disorders.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Giving the immune system a double boost against cancer
Scienmag
OCTOBER 30, 2020
Credit: CSHL, 2020 Cancer immunotherapies, which empower patients’ immune systems to eliminate tumors, are revolutionizing cancer treatment. Many patients respond well to these treatments, sometimes experiencing long-lasting remissions. But some cancers remain difficult to treat with immunotherapy, and expanding the impact of the approach is a high priority.
Safety concerns lead Regeneron to halt testing of COVID-19 drug in some patients
Bio Pharma Dive
OCTOBER 30, 2020
A study monitoring board flagged a "potential safety signal" in some hospitalized COVID-19 patients who require breathing support, telling the biotech to modify its study protocol.
Moderna nears COVID-19 vaccine finish line as it wraps up study enrolment
pharmaphorum
OCTOBER 26, 2020
Moderna is close to completing its phase 3 trial of COVID-19 vaccine candidate mRNA-1273 after completing recruitment of the 30,000 subjects in the trial. It’s also revealed that more than 25,000 of them have already received the second dose of the shot in the COVE study , putting it in contention to be the first coronavirus vaccine company to be ready to file for emergency use authorisation in the US.
Election Implications for the U.S. and Global COVID-19 Response
BioSpace
OCTOBER 29, 2020
The U.S. – and global – response to the COVID-19 pandemic has been volatile at best. This is fair, considering that SARS-CoV-2 is a novel virus with a lethality we haven’t seen in more than a century.
Roles and Responsibilities of Specialized Clinical Supply Experts
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Could High-Protein Iced Tea Be the Next Big Beverage Trend?
XTalks
OCTOBER 27, 2020
In recent years, food companies have created products that go beyond taste and convenience and also offer functionality and health benefits. Now, beverages are starting to offer the same advantages. These beverages are categorized in the industry as “fusion beverages,” and offer consumers more than just a way to quench their thirst. One such fusion beverage is high-protein iced tea – a functional, refreshing beverage that has the potential to be the next big beverage trend.
Axovant shares sink on manufacturing delay for Parkinson's gene therapy
Bio Pharma Dive
OCTOBER 30, 2020
A longer-than-expected timeline for developing a new manufacturing process means a key study for Axovant's top gene therapy likely won't begin until 2022.
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial
pharmaphorum
OCTOBER 27, 2020
Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to date suggest it is unlikely to be effective. The ACTIV-3 study was comparing bamlanivimab (also known as LY-CoV555 or LY3819253) and placebo when added to therapy with Gilead Sciences’ Veklury (remdesivir), which is already approved to treat COVID-19 requiring hospitalisation.
Study Suggests COVID-19 Infection Could Age the Brain, Reduce Cognition
BioSpace
OCTOBER 27, 2020
The report showed that in some cases, people who have recovered from the virus continued to exhibit significant cognitive deficits.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Novavax to start US Phase 3 COVID-19 vaccine trial next month
BioPharma Reporter
OCTOBER 27, 2020
Novavaxâs Phase 3 COVID-19 vaccine trial in the UK has been expanded to 15,000 participants; while a 30,000 strong Phase 3 clinical trial is due to start in the US and Mexico next month.
EQRx builds cancer drug pipeline as plans to challenge big pharma take shape
Bio Pharma Dive
OCTOBER 27, 2020
The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy.
Oxford start-up Base Genomics acquired by Exact Sciences
Pharma Times
OCTOBER 28, 2020
Acquisition will enable Base Genomics to accelerate clinical and commercial development
AbCellera Enters Pact with Kodiak Sciences to Develop Eye Disease Antibodies
BioSpace
OCTOBER 29, 2020
AbCellera and Kodiak Sciences have announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications. The two companies originally entered a partnership in August 2016.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Let's personalize your content